Chimerix, Inc. (NASDAQ:CMRX) Cut to “Hold” at Zacks Investment Research
Chimerix, Inc. (NASDAQ:CMRX) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Thursday.
According to Zacks, “Chimerix, Inc. engages in the discovery, development and commercialization of oral antiviral therapeutics for various medical needs. The Company is developing various product candidates for the treatment of dsDNA viruses, HIV, hepatitis C, influenza and smallpox which are under different phases of clinical development. It is also screening our proprietary Chimerix Chemical Library for compounds with activity against dengue virus, malaria and tuberculosis. Chimerix, Inc. is headquartered in Durham, North Carolina. “
Other analysts have also issued research reports about the company. Cowen and Company reaffirmed a “hold” rating and set a $6.00 price objective on shares of Chimerix in a research report on Friday, April 28th. FBR & Co reaffirmed a “hold” rating and set a $7.00 price objective on shares of Chimerix in a research report on Monday, May 1st.
Shares of Chimerix (NASDAQ CMRX) traded down 6.11% on Thursday, reaching $4.46. The company had a trading volume of 270,412 shares. The stock’s market capitalization is $209.83 million. The company’s 50 day moving average price is $5.17 and its 200-day moving average price is $5.45. Chimerix has a 1-year low of $3.66 and a 1-year high of $6.64.
Chimerix (NASDAQ:CMRX) last announced its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.05. The company had revenue of $0.68 million for the quarter, compared to analyst estimates of $1.28 million. Chimerix had a negative return on equity of 24.68% and a negative net margin of 1,514.27%. Equities analysts predict that Chimerix will post ($1.68) EPS for the current year.
Several hedge funds have recently bought and sold shares of CMRX. Teachers Advisors LLC raised its stake in Chimerix by 0.3% in the fourth quarter. Teachers Advisors LLC now owns 69,888 shares of the biopharmaceutical company’s stock worth $321,000 after buying an additional 204 shares in the last quarter. Bank of Montreal Can raised its stake in Chimerix by 3.8% in the first quarter. Bank of Montreal Can now owns 39,300 shares of the biopharmaceutical company’s stock worth $251,000 after buying an additional 1,448 shares in the last quarter. American International Group Inc. raised its stake in Chimerix by 7.1% in the first quarter. American International Group Inc. now owns 26,281 shares of the biopharmaceutical company’s stock worth $168,000 after buying an additional 1,733 shares in the last quarter. Nationwide Fund Advisors raised its stake in Chimerix by 5.9% in the first quarter. Nationwide Fund Advisors now owns 35,573 shares of the biopharmaceutical company’s stock worth $227,000 after buying an additional 1,977 shares in the last quarter. Finally, Alps Advisors Inc. raised its stake in Chimerix by 5.5% in the second quarter. Alps Advisors Inc. now owns 42,023 shares of the biopharmaceutical company’s stock worth $229,000 after buying an additional 2,178 shares in the last quarter. 65.63% of the stock is currently owned by institutional investors and hedge funds.
Chimerix Company Profile
Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Chimerix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.